EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC 4.0

OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine

Sanjay Cheema iD, Susie Lagrata, Khadija Rerhou Rantell, Maha Ahmed, Salwa Kamourieh, Manjit Singh Matharu iD

Cephalalgia · 2025

DOI: 10.1177/03331024251317448 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cephalalgia, 2025. Verfasst von Sanjay Cheema und 5 weiteren Autor:innen. Beteiligte Einrichtung: Headache and Facial Pain Group, University College London Queen Square Institute of Neurology, London, UK. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Migraine Disorders, Headache Disorders, Neuromuscular Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New daily persistent headache (NDPH) is an often treatment-refractory primary headache disorder with a lack of evidence base for treatment.

Methods

We performed an observational study using prospectively collected data in consecutive patients with NDPH, chronic migraine with daily headache (daily-CM) and without daily headache (non-daily-CM). Patients were treated with two cycles of OnabotulinumtoxinA. Propensity score matching was used to control for imbalances between the groups. The primary outcome measure was the proportion who experienced a ≥ 30% improvement in monthly moderate-to-severe headache days at 24 weeks.

Results

We included 58 patients with NDPH, 148 with daily-CM, and 84 with non-daily-CM. In NDPH, 34.5% of patients experienced a ≥ 30% improvement in monthly moderate-to-severe headache days, compared to 43.2% in daily-CM and 51.2% in non-daily CM. In NDPH, 6.9% experienced an improvement in monthly headache days, 27.6% an improvement in headache severity, 25.9% a ≥ 6 point improvement in HIT-6 score, and 59% a patient reported improvement. There was no significant difference in response rates between the three groups. Adverse event rates were similar in all groups and there were no serious adverse events.

Conclusion

OnabotulinumtoxinA is effective in approximately 1/3 patients with NDPH and has a favourable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AMigraine DisordersHeadache DisordersNeuromuscular AgentsHumansFemaleMaleAdultMiddle AgedTreatment OutcomeProspective Studies

Stichwörter der Autor:innen

Migrainenew daily persistent headacheonabotulinumtoxinAoutcome measures

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

  • Headache and Facial Pain Group, University College London Queen Square Institute of Neurology, London, UK.
  • Headache and Facial Pain Group, The National Hospital for Neurology and Neurosurgery, London, UK.
  • Biostatistics, Education Unit, University College London Queen Square Institute of Neurology, London, UK.

ORCID-Profile: Sanjay Cheema, Manjit Singh Matharu

Zitieren

APA

Cheema, S., Lagrata, S., Rantell, K. R., Ahmed, M., Kamourieh, S., & Matharu, M. S. (2025). OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine. Cephalalgia. https://doi.org/10.1177/03331024251317448

Vancouver

Cheema S, Lagrata S, Rantell KR, Ahmed M, Kamourieh S, Matharu MS. OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine. Cephalalgia. 2025. doi:10.1177/03331024251317448

BibTeX
@article{Cheema2025,
  author = {Cheema, Sanjay and Lagrata, Susie and Rantell, Khadija Rerhou and Ahmed, Maha and Kamourieh, Salwa and Matharu, Manjit Singh},
  title = {OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine},
  journal = {Cephalalgia},
  year = {2025},
  doi = {10.1177/03331024251317448}
}
Kostenlos starten →